tiprankstipranks
Trending News
More News >
Healthequity (HQY)
NASDAQ:HQY

Healthequity (HQY) AI Stock Analysis

Compare
884 Followers

Top Page

HQY

Healthequity

(NASDAQ:HQY)

Select Model
Select Model
Select Model
Outperform 76 (OpenAI - 4o)
Rating:76Outperform
Price Target:
$111.00
▲(14.68% Upside)
HealthEquity's strong financial performance and positive earnings call are the primary drivers of its stock score. The company's robust growth metrics and strategic initiatives position it well for future success. However, the high P/E ratio suggests overvaluation, and technical indicators show neutral momentum, which tempers the overall score.
Positive Factors
Strong Financial Growth
The significant increase in revenue, net income, and EBITDA reflects robust operational performance, indicating strong market demand and effective cost management, which supports long-term growth potential.
HSA and Account Growth
The growth in HSA accounts and assets enhances the company's market position and revenue base, providing a stable foundation for future expansion and increased customer engagement.
Positive Legislative Environment
Supportive legislative developments could expand the market for HSAs, aligning with HealthEquity's mission and potentially driving further growth in account adoption and revenue.
Negative Factors
Macro Environment Challenges
Economic uncertainties may hinder new member acquisition, impacting growth prospects. A weak labor market could reduce the number of potential HSA participants, affecting long-term revenue growth.
Potential Pricing Pressure
Pricing pressures could compress margins and affect revenue from premium account types, challenging the company's ability to maintain profitability in competitive segments.
Equity Utilization
While financial stability is strong, optimizing equity utilization is crucial for sustaining growth. Inefficient use of equity could limit the company's ability to invest in future opportunities and maintain competitive advantages.

Healthequity (HQY) vs. SPDR S&P 500 ETF (SPY)

Healthequity Business Overview & Revenue Model

Company DescriptionHealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides mutual fund investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. The company was incorporated in 2002 and is headquartered in Draper, Utah.
How the Company Makes MoneyHealthequity generates revenue through a variety of channels, primarily from account administration fees, investment income, and interchange fees associated with the use of debit cards linked to HSAs. The company charges employers and individuals for managing their health savings accounts, which includes providing online tools, customer service, and compliance support. Additionally, Healthequity earns income from the interest on cash balances held in HSA accounts and from investment management fees when account holders choose to invest their funds in various investment options. Partnerships with employers, insurance carriers, and third-party administrators also significantly contribute to its earnings by expanding its customer base and enhancing the value of its offerings in the competitive healthcare market.

Healthequity Earnings Call Summary

Earnings Call Date:Dec 03, 2025
(Q3-2026)
|
% Change Since: |
Next Earnings Date:Mar 24, 2026
Earnings Call Sentiment Positive
HealthEquity demonstrated strong financial performance, strategic growth in accounts, and new platform launches. The company faces some macroeconomic challenges and potential pricing pressures but remains optimistic about future growth and legislative support.
Q3-2026 Updates
Positive Updates
Impressive Financial Growth
Revenue increased by 7%, net income surged by 806%, and adjusted EBITDA rose by 20% year over year. Gross margin reached 71%, with an adjusted EBITDA margin of 40%.
HSA and Account Growth
HealthEquity ended Q3 with over 17 million total accounts, including more than 10 million HSAs. HSA balances grew 8%, contributing to a 15% increase in HSA assets.
Successful Launch of New Platforms
Launched a new direct HSA enrollment platform and expanded the HealthEquity Marketplace platform, providing access to affordable healthcare solutions.
Strong Balance Sheet and Cash Flow
Cash on hand was $309 million, with $339 million generated from operations in the first nine months of fiscal '26. The company repurchased $94 million of shares, with $259 million remaining on the repurchase authorization.
Positive Legislative Environment
Policymakers in Washington are considering options to expand HSA availability, aligning with HealthEquity's mission to empower healthcare consumers.
Investment in Security and AI
Investments in fraud prevention, AI service technologies, and secure mobile experiences resulted in fraud costs below targets and improved service margins.
Negative Updates
Challenges in Macro Environment
Macro uncertainties, including a soft labor market, could affect new member growth and overall industry dynamics.
Potential Pricing Pressure
Pricing pressure is expected at the high end of the market, potentially impacting revenue profiles for certain account types.
Company Guidance
During the HealthEquity Third Quarter 2026 Earnings Call, the company reported strong financial performance and raised its outlook for fiscal 2026. Key metrics highlighted included a 7% increase in revenue year-over-year, an impressive 806% rise in net income, and a 20% growth in adjusted EBITDA, with a gross margin of 71% and an adjusted EBITDA margin of 40%. Health Savings Accounts (HSAs) experienced a 6% growth, with total accounts increasing by 5% and HSA assets rising by 15%. The company ended the quarter with over 17 million total accounts, including more than 10 million HSAs. HealthEquity also emphasized its strategic focus on helping members save, spend, and invest more effectively for their health, while addressing rising healthcare costs. Looking ahead, for fiscal 2026, the company expects revenue between $1.302 billion and $1.312 billion, GAAP net income between $197 million and $205 million, and adjusted EBITDA between $555 million and $565 million.

Healthequity Financial Statement Overview

Summary
Healthequity exhibits a strong financial position with impressive revenue growth, profitability, and cash flow generation. The significant reduction in debt enhances financial stability, while robust margins and cash flow ratios indicate efficient operations. The company is well-positioned for continued growth, though it should maintain focus on optimizing equity utilization to sustain its positive trajectory.
Income Statement
85
Very Positive
Healthequity has demonstrated strong revenue growth with a TTM increase of 1.71% and consistent improvement over the past years. The company maintains robust profitability with a gross profit margin of 67.72% and a net profit margin of 14.86% in the TTM. EBIT and EBITDA margins are also healthy at 17.36% and 32.47%, respectively, indicating efficient operations. Overall, the income statement reflects a positive growth trajectory and strong profitability.
Balance Sheet
78
Positive
The balance sheet shows a significant reduction in debt, with a TTM debt-to-equity ratio of 0.02, down from 0.52 in the previous year, indicating improved financial stability. Return on equity has increased to 6.85%, reflecting better utilization of equity. The equity ratio remains strong, suggesting a solid capital structure. However, the company should continue to monitor its equity utilization to sustain growth.
Cash Flow
82
Very Positive
Cash flow analysis reveals a substantial increase in free cash flow growth at 17.70% in the TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 3.44, showing efficient conversion of income to cash. The free cash flow to net income ratio is high at 0.96, suggesting effective cash management. Overall, the cash flow statement reflects strong liquidity and operational efficiency.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.20B999.59M861.75M756.56M733.57M
Gross Profit777.26M622.64M490.09M423.71M415.33M
EBITDA337.54M282.42M171.53M102.97M154.93M
Net Income96.70M55.71M-26.14M-44.29M8.83M
Balance Sheet
Total Assets3.45B3.16B3.09B3.11B2.71B
Cash, Cash Equivalents and Short-Term Investments295.95M403.98M254.27M225.41M328.80M
Total Debt1.11B933.14M994.49M1.01B1.07B
Total Liabilities1.33B1.13B1.19B1.25B1.33B
Stockholders Equity2.11B2.04B1.90B1.85B1.38B
Cash Flow
Free Cash Flow337.77M196.75M31.52M3.91M84.66M
Operating Cash Flow339.86M242.83M150.65M141.00M181.62M
Investing Cash Flow-505.45M-46.07M-119.13M-639.25M-96.96M
Financing Cash Flow57.57M-47.04M-2.67M394.86M52.42M

Healthequity Technical Analysis

Technical Analysis Sentiment
Positive
Last Price96.79
Price Trends
50DMA
96.38
Positive
100DMA
94.39
Positive
200DMA
94.95
Positive
Market Momentum
MACD
-0.58
Positive
RSI
47.53
Neutral
STOCH
41.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HQY, the sentiment is Positive. The current price of 96.79 is below the 20-day moving average (MA) of 99.77, above the 50-day MA of 96.38, and above the 200-day MA of 94.95, indicating a neutral trend. The MACD of -0.58 indicates Positive momentum. The RSI at 47.53 is Neutral, neither overbought nor oversold. The STOCH value of 41.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HQY.

Healthequity Risk Analysis

Healthequity disclosed 41 risk factors in its most recent earnings report. Healthequity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Healthequity Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$8.27B44.369.01%12.20%98.75%
72
Outperform
$8.26B34.9824.61%20.21%44.14%
71
Outperform
$1.97B102.861.62%10.67%
70
Outperform
$3.91B-9.0550.67%-578.00%
67
Neutral
$6.59B61.004.25%17.23%
59
Neutral
$2.34B-103.210.42%2.97%-21.26%-119.34%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HQY
Healthequity
96.79
3.62
3.89%
OMCL
Omnicell
43.86
-1.46
-3.22%
PINC
Premier
28.26
7.12
33.68%
DOCS
Doximity
43.85
-9.43
-17.70%
BTSG
BrightSpring Health Services, Inc.
36.54
17.66
93.54%
HNGE
Hinge Health, Inc. Class A
49.70
9.54
23.75%

Healthequity Corporate Events

HealthEquity Inc. Reports Strong Q2 Earnings and Growth
Sep 4, 2025

HealthEquity Inc. recently held its earnings call, revealing a generally positive sentiment despite some challenges in the macroeconomic environment. The company showcased strong financial performance, legislative victories for Health Savings Accounts (HSAs), and technological advancements, all contributing to an optimistic outlook.

HealthEquity, Inc. Reports Strong Q2 Financial Results
Sep 3, 2025

HealthEquity, Inc. is a leading provider of health savings accounts (HSAs) and other consumer-directed benefits, partnering with employers and health plan providers to empower healthcare consumers with financial tools and resources.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 05, 2025